Liver mass surgery

Jump to navigation Jump to search

Liver Mass Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differential Diagnosis

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Evaluation of Liver Mass

Staging

History and Symptoms

Physical Examination

Laboratory Studies

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Liver mass surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Liver mass surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Liver mass surgery

CDC on Liver mass surgery

Liver mass surgery in the news

Blogs on Liver mass surgery

Directions to Hospitals Treating bone or soft tissue mass

Risk calculators and risk factors for Liver mass surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Surgery

 In the majority of cases of benign hepatic tumors, patients are asymptomatic, and no treatment is indicated. The main indication for treatment is the presence of significant clinical symptoms or suspicion of malignancy or fear of malignant transformation. Surgery is the mainstay of treatment for benign liver lesions. Management of lesions also depends upon:

  • Symptoms
  • Size
  • Number
  • Location
  • Certainty of the diagnosis

Surgical options

  • Embolization
  • ERCP
  • Liver resection
  • Liver transplantation

Indications for Surgery

  • Bleeding tumor
  • Solitary Symptomatic Tumors
Asymptomatic Symptomatic
Surgical Non-Surgical options
Indications Options
Hepatic adenoma The European Association for Study of the Liver recommends
  • Discontinuation of contraceptive medication
  • Close observation of the lesion with repeated imaging and alpha fetoprotein.
    • Contrast-enhanced MRI at a six 6 month interval to determine if there is regression.
Indcations
  • Symptomatic patients
  • Large lesions (>5 cm).
  • Enucleation
  • Resection
  • Liver transplantation
  • Transarterial embolization
  • Radiofrequency ablation
Hepatic Hemangioma
  • Patients with lesions <1.5 cm
    • Reassurance
    • Observation
  • Patients with a rapid growth of a hemangioma or with lesions >5 cm
    • Repeat imaging in 6 to 12 months.
  • Abdominal pain
  • Symptoms suggestive of extrinsic compression of adjacent structures
  • Liver resection
  • Enucleation
  • Hepatic artery ligation
  • Liver transplantation
  • Hepatic artery embolization
  • Radiotherapy
  • Interferon alfa-2a 
Focal nodular hyperplasia

Hepatic adenoma

Asymptomatic woman on OCPs with a small adenoma

The European Association for Study of the Liver recommends

  • Discontinuation of contraceptive medication
  • Close observation of the lesion with repeated imaging and alpha fetoprotein.
    • Contrast-enhanced magnetic resonance imaging at a six month interval to determine if there is regression of a large adenoma to less than 5 cm.
  • Patients with hepatic adenomas that do not resolve or that enlarge after six months of observation should undergo treatment.

Symptomatic patients and those with large adenomas

  • Surgical resection is recommended for all symptomatic patients with hepatic adenoma and those with large lesions (>5 cm).
  • Surgical options include :
    • Enucleation
    • Resection
    • Liver transplantation
  • Nonsurgical interventions include
    • Transarterial embolization
    • Radiofrequency ablation

Hepatic Hemangioma

  • Asymptomatic patients
    • Patients with lesions <1.5 cm, are reassured and observed.
    • Follow-up imaging in patients with hemangiomas ≤5 cm in size is usually not recommended.
    • Patients with rapid growth of a hemangioma or with lesions >5 cm it is recommended to repeat imaging in 6 to 12 months.
    • It is recommended not perform additional imaging if there is no change in the size of the lesion.  
  • Symptomatic patients
    • Patients who have pain or symptoms suggestive of extrinsic compression of adjacent structures should be considered for surgical options.
    • Surgical options include 
      • Liver resection
      • Enucleation
      • Hepatic artery ligation
      • Liver transplantation
    • Non-surgical techniques include
      • Hepatic artery embolization
      • Radiotherapy
      • Interferon alfa-2a 

Focal nodular hyperplasia

  • Due to their benign nature of focal nodular hyperplasia, there is no indication for therapy unless they are symptomatic.
  • Follow-up studies at three and six months will often be sufficient to confirm the stability of the lesion and its benign nature, after which no long-term follow-up is required routinely.
  • Surgery should be reserved for symptomatic FNH lesion.

References